|
Lynk Biotechnologies Pte Ltd
|
|
Lynk Biotechnologies Pte Ltd (Lynk Biotech) is a Singapore-based pharmaceutical company that was spun off from National University of Singapore (NUS) in the year 2000 with S$1 million investment from angel investors. The company was started by Associate Professor Lee Chee Wee from Yong Loo Lin School of Medicine, NUS. Dr. Lee Chee Wee is also a well-known Singaporean inventor and one of the founding members of Fellowship of Inventors, Singapore. As the first biotechnology start-up in Singapore, Lynk Biotech is closely watched by many in the industry. It has received much media coverage throughout the years, appearing in Singapore’s leading English newspapers - The Straits Times and The Business Times, Mediacorp Singapore’s online news network - channelnewsasia.com and respected industry journals - Bioventrure View and SI News. Capabilities Lynk Biotech is fully equiped with an R&D and Quality department, to a GMP certified manufacturing facility, warehouse and distribution arm. With these infrastructure in place, it has the capability to develop its own proprietary technologies, translate them to efficacious products and commercialise them. This is very rare of a Singapore company which is one of the reasons that put Lynk in the spotlight. Lynk is dedicated to the application of revolutionary technologies for the design and development of innovative products and services, aimed at improving the quality of life and well being for all. It has since developed a strong portfolio of platform technologies and applied them to products that have been made available for sale. Transdermal Technology One of the platform technologies developed by Lynk Biotech is its proprietary Transdermal Technology for transdermal delivery of drug. The technology enables water-soluble molecules to be delivered across the skin into the body. Transdermal drug delivery is a process whereby drugs are delivered to the body while bypassing the gastrointestinal tract (GI). This method allows aversion of GI irritation that occurs with frequent oral medication. It is said that the first of transdermal drug delivery commercialized in 1979, where a motion sickness patch was approved for prescription by US Food and Drug Administration. Following that, other transdermal patches commercialized to resolve various troubles such as nicotine addiction, menopause and pain relief. The advantage of these transdermal delivery is that it allows maximal effectiveness of the drug effects by releasing consistent levels into the blood stream rather than peak-and-valley effect, which often is the cause of undesirable side effects. Transdermal Glucosamine Cream With its Transdermal Technology, Lynk Biotech develops a Transdermal Glucosamine Cream (TGC) for treatment of osteoarthritis. Glucosamine is an amino sugar that forms one of the primary building blocks of cartilage and is essential for maintenance of cartilage. Glucosamine is widely prescribed for the treatment of osteoarthritis - a progressive degenerative joint disease (DJD) caused by wear and tear of joint cartilage. Transdermal glucosamine cream allows water-soluble glucosamine to be delivered through the skin directly into the blood stream at the affected joint areas. This shortens the time required for the glucosamine to reach the affected joints, maintains a continual high glucosamine effect for hours after initial application and largely reduces interaction with other drugs or food. Hence it is convenient and has no contraindication for users with oral regime. 
|
| < Prev | Next > |
|---|
Main Menu
| Home |
| Articles |
| Search |
| Submit Article |
| Contact Us |
| Donate to Wikibin |
